STOPCAP M0, docetaxel, systematic review and aggregate data meta-analysis
Addition of docetaxel to standard of care in men with localised hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
Does docetaxel improve survival for men with prostate cancer that has not spread?
What was this study about?
A systematic review and aggregate data meta-analyses was carried out bringing together trials that looked at whether adding docetaxel to standard of care, improved survival in men with localised prostate cancer
What difference did this study make?
Docetaxel showed an improvement in failure-free survival in men whose disease has not spread (non-metastatic) but there is less evidence of a benefit on survival, at this point in time.
Vale CL, Burdett S, Rydzewska LH, Albiges L, Clarke NW, Fisher D, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncology. 2016;17(2):243-56
Details of this and other reviews in metastatic, hormone-sensitive prostate cancer are available here www.stopcapm1.org
Type of study
Who funded the study?
The Medical Research Council.
When did it take place?
This study was fully published in 2016 and brought together the results of trials that were carried out between 2002 and 2013.
Where did it take place?
This study was done at the MRC Clinical Trials Unit at UCL but brings together the results of trials from all over the world.
Who was included?
This study brought together 4 trials (2348 patients) that studied the addition of docetaxel to standard of care in men with hormone-sensitive prostate cancer that had not spread.